

To: (10)(2e) [] (10)(2e) @rivm.nl
From: (10)(2e)
Sent: Mon 7/13/2020 5:55:31 PM
Subject: FW: FOR ACTION: Group authorship for: Geographic and temporal distribution of SARS-CoV-2 clades in the WHO European Region during the first half of 2020
Received: Mon 7/13/2020 5:55:32 PM
[Author feedback template group.xlsx](#)
[Geographic and temporal distribution of SARS-CoV-2 clades in the WHO European Region during the first half of 2020 FOR REVIEW.docx](#)

Voorbeeld van hoe ECDC deelt met enorme hoeveelheden auteurs *

< (10)(2e) @insa.min-saude.pt'; (10)(2e) @insa.min-saude.pt' < (10)(2e) @insa.min-saude.pt';
 (10)(2e) @cantacuzino.ro' <(10)(2e) @cantacuzino.ro>; (10)(2e) @uvzsr.sk' < (10)(2e) @uvzsr.sk>;
 (10)(2e) @nlzoh.si' < (10)(2e) @nlzoh.si>; (10)(2e) @nlzoh.si' < (10)(2e) @nlzoh.si>; (10)(2e) @iscii.es'
 <(10)(2e) @iscii.es>; (10)(2e) @clinic.cat' <(10)(2e) @clinic.cat>; (10)(2e) @saludcastillayleon.es'
 (10)(2e) @saludcastillayleon.es'; (10)(2e) @iscii.es' < (10)(2e) @iscii.es>;
 (10)(2e) @folkhalsomyndigheten.se' < (10)(2e) @folkhalsomyndigheten.se>; (10)(2e) @crick.ac.uk'
 <(10)(2e) @crick.ac.uk>; (10)(2e) @ggc.scot.nhs.uk' <(10)(2e) @ggc.scot.nhs.uk>; (10)(2e) @ggc.scot.nhs.uk'
 (10)(2e) @ggc.scot.nhs.uk'; (10)(2e) @wales.nhs.uk' <(10)(2e) @wales.nhs.uk>;
 (10)(2e) @nhs.net' <(10)(2e) @nhs.net>; (10)(2e) @phe.gov.uk' <(10)(2e) @phe.gov.uk>;
 (10)(2e) @phe.gov.uk' <(10)(2e) @phe.gov.uk>; (10)(2e) @meduniwielen.ac.at'
 <(10)(2e) @meduniwielen.ac.at>; (10)(2e) @sciensano.be' <(10)(2e) @sciensano.be>;
 (10)(2e) @ncipd.org' <(10)(2e) @ncipd.org>; (10)(2e) @hzjz.hr' <(10)(2e) @hzjz.hr>; (10)(2e) @hzjz.hr'
 <(10)(2e) @hzjz.hr>; (10)(2e) @moh.gov.cy' <(10)(2e) @moh.gov.cy>; (10)(2e) @mphs.moh.gov.cy'
 <(10)(2e) @mphs.moh.gov.cy>; (10)(2e) @cytanet.com.cy' <(10)(2e) @cytanet.com.cy>; (10)(2e) @szu.cz'
 <(10)(2e) @szu.cz>; (10)(2e) @ssi.dk' <(10)(2e) @ssi.dk>; (10)(2e) @thl.fi' <(10)(2e) @thl.fi>; (10)(2e)
 (10)(2e) @santepubliquefrance.fr' <(10)(2e) @santepubliquefrance.fr>; (10)(2e) @santepubliquefrance.fr'
 <(10)(2e) @santepubliquefrance.fr>; (10)(2e) @rki.de' <(10)(2e) @rki.de>; (10)(2e) @rki.de' <(10)(2e) @rki.de>;
 (10)(2e) @keelpno.gr' <(10)(2e) @keelpno.gr>; (10)(2e) @keelpno.gr' <(10)(2e) @keelpno.gr>;
 (10)(2e) @nnk.gov.hu' <(10)(2e) @nnk.gov.hu>; (10)(2e) @nnk.gov.hu' <(10)(2e) @nnk.gov.hu>;
 (10)(2e) @landlaeknir.is' <(10)(2e) @landlaeknir.is>; (10)(2e) @hpsc.ie' <(10)(2e) @hpsc.ie>; (10)(2e) @hse.ie'
 <(10)(2e) @hse.ie>; (10)(2e) @hse.ie' <(10)(2e) @hse.ie>; (10)(2e) @opbg.net' <(10)(2e) @opbg.net>;
 (10)(2e) @iss.it' <(10)(2e) @iss.it>; (10)(2e) @spkc.gov.lv' <(10)(2e) @spkc.gov.lv>;
 (10)(2e) @spkc.gov.lv' <(10)(2e) @spkc.gov.lv>; (10)(2e) @ulac.lt' <(10)(2e) @ulac.lt>;
 (10)(2e) @ms.etat.lu' <(10)(2e) @ms.etat.lu>; (10)(2e) @ms.etat.lu' <(10)(2e) @ms.etat.lu>;
 (10)(2e) @gov.mt' <(10)(2e) @gov.mt>; (10)(2e) @gov.mt' <(10)(2e) @gov.mt>; (10)(2e)
 <(10)(2e) @rivm.nl>; (10)(2e) @fhi.no' <(10)(2e) @fhi.no>; (10)(2e) @pzh.gov.pl'
 <(10)(2e) @pzh.gov.pl>; (10)(2e) @dgs.min-saude.pt' <(10)(2e) @dgs.min-saude.pt>; (10)(2e) @insp.gov.ro'
 <(10)(2e) @insp.gov.ro>; (10)(2e) @insp.gov.ro' <(10)(2e) @insp.gov.ro>; (10)(2e) @uvzsr.sk'
 <(10)(2e) @uvzsr.sk>; (10)(2e) @nijz.si' <(10)(2e) @nijz.si>; (10)(2e) @nijz.si' <(10)(2e) @nijz.si>; (10)(2e) @iscii.es'
 <(10)(2e) @iscii.es>; (10)(2e) @folkhalsomyndigheten.se' <(10)(2e) @folkhalsomyndigheten.se>;
 (10)(2e) @folkhalsomyndigheten.se' <(10)(2e) @folkhalsomyndigheten.se>; (10)(2e) @folkhalsomyndigheten.se'
 <(10)(2e) @folkhalsomyndigheten.se>; (10)(2e) @folkhalsomyndigheten.se'
 <(10)(2e) @folkhalsomyndigheten.se>; (10)(2e) @auth.gr' <(10)(2e) @auth.gr>; (10)(2e) @bio.aau.dk' <(10)(2e) @bio.aau.dk>;
 <(10)(2e) @ssi.dk' <(10)(2e) @ssi.dk>; (10)(2e) @helsinki.fi' <(10)(2e) @helsinki.fi>; (10)(2e) @univ-
 lyon1.fr'; (10)(2e) @pasteur.fr' <(10)(2e) @pasteur.fr>; (10)(2e) @chu-toulouse.fr' <(10)(2e) @chu-
 toulouse.fr>; (10)(2e) @univ-lyon1.fr' <(10)(2e) @univ-lyon1.fr>;
 (10)(2e) @bundeswehr.org' <(10)(2e) @bundeswehr.org>; (10)(2e) @med.uni-
 duesseldorf.de' <(10)(2e) @med.uni-duesseldorf.de>; (10)(2e) @charite.de' <(10)(2e) @charite.de>;
 (10)(2e) @genzentrum.lmu.de' <(10)(2e) @genzentrum.lmu.de>; (10)(2e) @med.duth.gr' <(10)(2e) @med.duth.gr>;
 (10)(2e) @gamma.ttk.pte.hu' <(10)(2e) @gamma.ttk.pte.hu>; (10)(2e) @decode.is' <info@decode.is>; (10)(2e) @ucd.ie'
 <(10)(2e) @ucd.ie>; (10)(2e) @icgeb.org' <(10)(2e) @icgeb.org>; (10)(2e) @izs.it'
 <(10)(2e) @izs.it>; (10)(2e) @unisr.it' <(10)(2e) @unisr.it>; (10)(2e) @unimi.it'
 <(10)(2e) @unimi.it>; (10)(2e) @unicamillus.org' <(10)(2e) @unicamillus.org>; (10)(2e) @irsa.cnr.it'
 <(10)(2e) @irsa.cnr.it>; (10)(2e) @univpm.it' <(10)(2e) @univpm.it>; (10)(2e) @inmi.it'
 <(10)(2e) @inmi.it>; (10)(2e) @iss.it' <(10)(2e) @iss.it>; (10)(2e) @biomed.lu.lv' <(10)(2e) @biomed.lu.lv>;
 (10)(2e) @nvspl.lt' <(10)(2e) @nvspl.lt>; (10)(2e) @lns.etat.lu' <(10)(2e) @lns.etat.lu>;
 (10)(2e) @erasmusmc.nl' <(10)(2e) @erasmusmc.nl>; (10)(2e) @wur.nl' <(10)(2e) @wur.nl>;
 (10)(2e) @biotech.ug.edu.pl' <(10)(2e) @biotech.ug.edu.pl>; (10)(2e) @uj.edu.pl'
 <(10)(2e) @uj.edu.pl>; (10)(2e) @igc.gulbenkian.pt' <(10)(2e) @igc.gulbenkian.pt>; (10)(2e) @vector.nsk.su' <(10)(2e) @vector.nsk.su>;
 (10)(2e) @influenza.spb.ru' <(10)(2e) @influenza.spb.ru>; (10)(2e) @savba.sk' <(10)(2e) @savba.sk>;
 (10)(2e) @mf.uni-lj.si' <(10)(2e) @mf.uni-lj.si>; (10)(2e) @nlzoh.si' <(10)(2e) @nlzoh.si>; (10)(2e) @vhir.org'
 <(10)(2e) @vhir.org>; (10)(2e) @idipaz.es' <(10)(2e) @idipaz.es>; (10)(2e) @uab.cat'
 <(10)(2e) @uab.cat>; (10)(2e) @uv.es' <(10)(2e) @uv.es>; (10)(2e) @uv.es>; (10)(2e) @cogconsortium.uk'
 <(10)(2e) @cogconsortium.uk>; (10)(2e) @glasgow.ac.uk' <(10)(2e) @glasgow.ac.uk>; (10)(2e) @cardiff.ac.uk'
 <(10)(2e) @cardiff.ac.uk>; (10)(2e) @nhslothian.scot.nhs.uk' <(10)(2e) @nhslothian.scot.nhs.uk>;
 (10)(2e) @cemm.oeaw.ac.at' <(10)(2e) @cemm.oeaw.ac.at>; (10)(2e) @uliege.be' <(10)(2e) @uliege.be>;
 (10)(2e) @kuleuven.be' <(10)(2e) @kuleuven.be>; (10)(2e) @itg.be' <(10)(2e) @itg.be>; (10)(2e) @UGent.be'

< (10)(2e) [UGent.be]; (10)(2e) [irb.hr] < (10)(2e) [irb.hr]; (10)(2e) [lfmotol.cuni.cz]
 < (10)(2e) [lfmotol.cuni.cz]; (10)(2e) [lfmotol.cuni.cz] < (10)(2e) [lfmotol.cuni.cz]; 'Sebastian Maurer-Stroh'
 < (10)(2e) [gmail.com]>
Cc: (10)(2e) < (10)(2e) [ecdc.europa.eu>; PHE Support.Microbiology < (10)(2e) [ecdc.europa.eu];
 (10)(2e) < (10)(2e) [ecdc.europa.eu]; (10)(2e) < (10)(2e) [who.int]>

Subject: FOR ACTION: Group authorship for: Geographic and temporal distribution of SARS-CoV-2 clades in the WHO European Region during the first half of 2020

Dear colleagues,

You and your collaborators have previously been invited* to discuss the scope and participate in the creation of a manuscript that outlines the genetic clades and lineages of SARS-CoV-2 in the WHO European Region during the pandemic so far.

During a call on 2 June open to all laboratories in the WHO European Region contributing sequences to GISAID, we decided on the scope and formed a smaller writing group for drafting the manuscript.

The manuscript has now been drafted by the writing group together with representatives from the three nomenclatures included in the manuscript, and it is time to consult you on the draft.

We have decided to open up the number of authors per institute; you can contribute with as many authors as you want as long as they all fulfil the eligibility criteria, see below.

Please immediately forward this email to people in your institution and in your collaborating institutions that may be eligible and interested.

We are aware that people may be on holidays; please contact them anyway if you know that they are interested.

Please note that the figures and numbers in the manuscript will be updated with the newest GISAID data snapshot just before submission.

Please read the instructions carefully:

- The deadline for this consultation is **Thursday July 9th 23:59**
- To be eligible as an author, the person must fulfil **all** these **four** criteria:
 - Contributed actively to generation and/or analysis of sequence data submitted to GISAID from a country in the WHO European Region
 - Have critically revised the manuscript for intellectual content
 - Agree to be held accountable for the intellectual content
 - After the round of revisions approve the final version
- There is an excel template attached to this email, fill it in individually, per institution, or per several institutions (the fewer excel files the better), rename the file to reflect your institution's name and return it by email. Each author must personally have confirmed the content of each field in their row.
- All comments must go into the excel file, no comments in the manuscript itself please.
- As you already had the possibility to comment on the scope during the 2 June call, please do not include comments that involve a change in scope of the manuscript.

Due to the strict journal authorship guidelines, we will not be able to include as authors the persons that have not filled in the form and responded by the deadline (July 9th). Also note that the deadline for the approval for the final version will be shorter, so please check your email.

Thanks for your contributions, we are looking forward to your revision.

Best wishes,
 (10)(2e)

* If you submitted sequence data to GISAID for the first time in June, you may previously not have been invited.



(10)(2e)
Principal Expert Applied Molecular
Epidemiology
Surveillance, PHF
Phone + (10)(2e)
(10)(2e) @ecdc.europa.eu

**European Centre for
Disease Prevention and Control (ECDC)**
Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone + (10)(2e) / Fax +46 (10)(2e)
www.ecdc.europa.eu

Follow ECDC on: [f](#) [t](#) [in](#) [y](#)



Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.